A Pilot Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG With Escalating Doses of Anti-PD-1 Antibody BMS-936558 for Patients With Unresectable Stages III/IV Melanoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Nivolumab (Primary) ; Cancer vaccine NY-ESO-1; Gp100-MART-1 peptides vaccine; Montanide ISA-51
- Indications Malignant melanoma
- Focus Therapeutic Use
- 22 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 18 Apr 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.
- 16 Aug 2016 Planned End Date changed from 1 Nov 2016 to 1 Mar 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History